For Immediate Release: January 15, 2015
Medpace Strengthens Medical Leadership in Neuroscience Drug Development Dr. James J. Vornov Joins Medpace as Vice President, Medical Affairs
CINCINNATI, OH — (January 15, 2015) – James J. Vornov, M.D., Ph.D. has joined Medpace as Vice President Medical Affairs where he will provide hands-on medical leadership to Sponsors of neuroscience clinical research. Medpace, a global drug and medical device Clinical Research Organization (CRO), is unique in its physician-driven approach to clinical research which gives Sponsors the advantage of early and ongoing insight and guidance from therapeutic experts throughout trial design and execution. Medpace medical doctors provide strategic direction for study design and planning, train operational staff, work with primary investigators, provide medical monitoring, and meet with regulatory agencies. Dr. Vornov joins a team of highly-experienced physicians and will strengthen Medpace’s ability to support global neuroscience trials.
About James J. Vornov, M.D., Ph.D.
Dr. Vornov is an internationally known clinician-scientist with broad knowledge of both neuroscience and drug development. He has worked in multiple CNS therapeutic areas having directed programs in Depression, Suicidal Ideation, Parkinson’s Disease treatment and diagnosis, stroke, neuropathic pain, diabetic and chemotherapy-induced peripheral neuropathies, anesthesia and brain tumors, with particular expertise in the rapid transition of compounds from the laboratory to clinical proof of concept through the use of Critical Path technologies such as biomarkers, PK/PD modeling, adaptive design and clinical trial simulation. Dr. Vornov has successfully brought multiple compounds into man to proof of concept and successful NDA submission, providing broad clinical trial design expertise, clinical pharmacology experience, operational excellence and global regulatory strategy development across a broad range of CNS diagnostics and therapeutics. Prior to joining Medpace, Dr. Vornov was Chief Medical Officer and SVP of Clinical Development at a private, development stage biopharmaceutical company. He provides Drug Development expertise to the Neurotranslational Program at the Brain Science Institute at the Johns Hopkins Medical School. Dr. Vornov received his B.A. in biology from Columbia University and his M.D. and Ph.D. from Emory University School of Medicine. He trained in Neurology at the Johns Hopkins Medical School where he served on the faculty for 10 years prior to transitioning to industry.
Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic and specialty areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, gastrointestinal diseases, regenerative medicine, pediatrics, and rare disease/orphan indications. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and six regions – the US, Europe, Central and Eastern Europe, India, Asia Pacific, and Africa. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.